LE WE PMID CA
Neoplasia (Tumor biology and immunology)3291Neubildung (Tumorbiologie und Immunologie)

15 PGDH15 hydroxyprostaglandin dehydrogenase

2 deoxyglucose

5T4 Oncotrophoblast glycoprotein

Abl

Adenosine

Angiogenesis

Antineoplastic agents (Novel target ideas)

Apoptosis

Autoantibodies Anti Tumor associated Antigens

Autophagy

B cell (Immunology)

B7H3

Bisphosphonates

Bystin

C EBPbeta

Cadherin switching

Cadherin

Calcium (Physiology Intestines)

CASR

CD1D

CD73

Cell (Quiscence)

Cell aging

Cell culture (Spheroids)

Cell cylce (BASKET)

Cell death (BASKET)

Cell differentiation

Cell Secretion (Exosomes)

Cell senescence

Centrosome

Chloroquine

CNS (Metabolism of injured CNS)

CNS (Neoplasia Glioblastoma)

CNS (Neoplasia Glioma)

CNS (Neoplasia Neuroblastoma)

Colon and rectum (Neoplasia)

Cross presentation

CRP

CXCR7

Data base (Medicine Biology Pharmacology)

Dendritic cell (Immunology)

DNA (Methylation)

DNA (Polymerase)

DNA (Repair and Toxicology)

DNA Vaccine

Drug repositioning

Efferocytosis

Endoglin

Endothelial cell (Circulating)

Endothelin

Epigenetics

Epithelio mesenchymal transition

Epithelium (BASKET)

Epoxyeicosatrienoic acid EET

ERS UFR (Pharmacology)

Extracellular matrix

Fatty acids (Biosynthesis)

Fibrosis

Focal adhesion kinase

Fucose

Fucosyltransferase

Ganglioside NGcGM3

Gene transfer

Genetic instability

GITR

GITRL

GLI

GLI1 protein family

Glutaminase

Glycolysis

Glycosphingolipid

Glycosylation

Hedgehog

Hes1

HIF1alpha und HIF1 (BASKET)

HLA G

HLA MHC class Ib

hnRNPA1

hnRNPA2

hnRNPI PTB

Human genetics (BASKET)

Hyaluronic acid

Hydroxyeicosatetraenoic acid HETE

Hypoxia (systemic)

IAP

IDO Indoleamine oxygenase

IGF1

IGFBP3

ILT3

Implantation (Development)

Interleukin17

Interleukin4

Ion channel (TRP Family)

Irgendwie seltsame Erkenntnisse

LET7

Leukemia and lymphoma (BASKET)

Lipoxin

Lung and bronchial system (Neoplasia NSCLC)

Lymphoma (Hodgkin)

Lysophosphatidate

Macrophages

Mammary gland (Development)

Mammary gland (Neoplasia)

Mast cells

Matrix metalloproteinase

Mesenkillers

MiRNA 21

Mitochondria (BASKET)

Mitochondria (Dysfunction)

Mitotic catastrophe

Morphine

Morphogenesis (Development)

MTOR

Multiphoton imaging

MUTYH

Myeloid derived suppressor cell

Myofibroblast

N Acetylglucosamine

Natural products

Neoplasia (Carcinogenesis)

Neoplasia (Dormancy)

Neoplasia (Invasion and metastasis)

Neoplasia (Oncology BASKET)

Neoplasia (Tumor biology and immunology)

Neoplasia (Tumor markers)

Neoplasia (Tumor stroma)

NEU3 Neuraminidase Sialidase

Neuropilin

Neurostatin

NFKB

Nitric oxide NO

NK cells

NKG2D

NKT cells

Notch

Obesity (BASKET)

OGG1

ORL (Neoplasia)

Osteoporosis

Oxygen (Hypoxia)

P53

Pancreas (Neoplasia)

PAR2

PAR4

PCP planar cell polarity

PD1

PDGF

Pentose shunt

Perforin

Perinucleolar compartment

Personalized medicine

Phosphatidic acid

Phospholipase D

PINCH

Plexins

PON2 Paraoxonase2

Prostaglandins

Prostate (Neoplasia)

Protein kinase B Akt

Proteoglycan

Proton pump inhibitors

Pttg

Pyruvate kinase

QA2

Quasispecies

Racotumomab ttGangliosidAntiID

Radiation therapy

Rapamycin

Receptor (RAGE)

Receptor (TGF beta family)

Receptor (Urokinase)

Receptor (Vitamin D)

Regeneration of tissues and other biologic structures

Regulatory T cell

RNA (MicroRNA)

RNA (non coding)

RNA (nRNA BASKET)

Sam68

Semaphorin

Sequencing (Nucleic acids)

Signal transduction

Sirtuin

Skin (Neoplasia Melanoma)

Smac

SNAIL

Sphingolipids

Statistics and trial design

Stearoyl CoA desaturase

Stem cell (Adult somatic derived reprogrammed)

Stem cell (BASKET)

Stem cell (Neoplasia)

Steroid hormones (BASKET)

Stomach (Neoplasia)

Stroma

T cell (gammadelta)

T cell (Th17)

Tastin

TGF beta

Throphinin

Tissue (Cell Biology)

Tissue factor

TMPRSS2

TNFAIP3 A20

Tolerance (Immunology)

TRPM1

TRPM8

TRPV6

Tuberculosis

Tuberous sclerosis

Twist

Uncoupling protein

Unfolded protein response

Urinary tract (Neoplasm)

Vaccine (Cellular)

Vaccine (Oncology)

Vasculogenic mimicry

Virus (RNA virus)

Warburg effect

Wnt beta Catenin TCF

Wound healing

1988  
1
Tumor growth and metastases in malignant disease. A review.
[3141546] J Med 19(3-4): 179-91 (1988)
2009  
2
Cell-derived microvesicles and cancer.
[19687520] Neth J Med 67(7): 266-73 (2009)
1987  
3
Cytotoxic cellular mediators of the immune response to neoplasia: a review.
[3321723] Yale J Biol Med 60(5): 409-19 (1987)
2004  
4
Pathophysiology of cerebral ischemia and brain trauma: similarities and differences.
[14747740] J Cereb Blood Flow Metab 24(2): 133-50 (2004)
2006  
5
Clinical implications of angiogenesis in cancers.
[17319453] Vasc Health Risk Manag 2(2): 97-108 (2006)
2005  
6
Pathophysiology of tumor neovascularization.
[17315600] Vasc Health Risk Manag 1(4): 277-90 (2005)
2000  
7
The role of polypeptide growth factors in human carcinomas: new targets for a novel pharmacological approach.
[10835099] Pharmacol Rev 52(2): 179-206 (2000)
2008  
8
AllergoOncology: the role of IgE-mediated allergy in cancer.
[18671772] Allergy 63(10): 1255-66 (2008)
2009  
9
Regulation of tumor immune surveillance and tumor immune subversion by tgf-Beta.
[20157598] Immune Netw 9(4): 122-6 (2009)
2000  
10
An overview of cancer immunotherapy.
[10849106] Immunol Cell Biol 78(3): 179-95 (2000)
1987  
11
1987  
12
2005  
13
Dendritic cell dysfunction in cancer: a mechanism for immunosuppression.
[16174093] Immunol Cell Biol 83(5): 451-61 (2005)
2008  
14
Immunoglobulin expression and its biological significance in cancer cells.
[18954554] Cell Mol Immunol 5(5): 319-24 (2008)
2007  
15
The dual effects of interleukin-18 in tumor progression.
[17976312] Cell Mol Immunol 4(5): 329-35 (2007)
2007  
16
5T4 oncotrophoblast glycoprotein: janus molecule in life and a novel potential target against tumors.
[17484803] Cell Mol Immunol 4(2): 99-104 (2007)
2007  
17
Enhancing immune responses for cancer therapy.
[17601371] Cell Mol Immunol 4(3): 173-84 (2007)
2005  
18
New concepts in tumor antigens: their significance in future immunotherapies for tumors.
[16368059] Cell Mol Immunol 2(5): 331-41 (2005)
2005  
19
Cytokine and immuno-gene therapy for solid tumors.
[16191413] Cell Mol Immunol 2(2): 81-91 (2005)
2004  
20
A global approach to tumor immunology.
[16225768] Cell Mol Immunol 1(4): 256-65 (2004)
2004  
21
Forcing tumor cells to present their own tumor antigens to the immune system: a necessary design for an efficient tumor immunotherapy.
[16219165] Cell Mol Immunol 1(3): 180-5 (2004)
2010  
22
Premetastatic milieu explained by TLR4 agonist-mediated homeostatic inflammation.
[20140009] Cell Mol Immunol 7(2): 94-9 (2010)
2004  
23
The immunobiology of cancer immunosurveillance and immunoediting.
[15308095] Immunity 21(2): 137-48 (2004)
1999  
24
The makings of a tumor rejection antigen.
[10514004] Immunity 11(3): 263-70 (1999)
1999  
25
A new era for cancer immunotherapy based on the genes that encode cancer antigens.
[10204484] Immunity 10(3): 281-7 (1999)
2007  
26
Cancer immunoediting from immune surveillance to immune escape.
[17386080] Immunology 121(1): 1-14 (2007)
2006  
27
Cancer immunosuppression and autoimmune disease: beyond immunosuppressive networks for tumour immunity.
[17005005] Immunology 119(2): 254-64 (2006)
2005  
28
Intratumoral immunotherapy: using the tumour against itself.
[15606790] Immunology 114(1): 11-22 (2005)
2001  
29
2008  
30
Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms.
[18250403] J Immunol 180(4): 2011-7 (2008)
2007  
31
Unique human tumor antigens: immunobiology and use in clinical trials.
[17277099] J Immunol 178(4): 1975-9 (2007)
2008  
32
Immune-mediated dormancy: an equilibrium with cancer.
[18515327] J Leukoc Biol 84(4): 988-93 (2008)
2006  
33
Monocyte/macrophage infiltration in tumors: modulators of angiogenesis.
[16997855] J Leukoc Biol 80(6): 1183-96 (2006)
2006  
34
Tumor growth or regression: powered by inflammation.
[16864602] J Leukoc Biol 80(4): 685-90 (2006)
2006  
35
Dual role of macrophages in tumor growth and angiogenesis.
[16864600] J Leukoc Biol 80(4): 705-13 (2006)
2006  
36
Tumor and lymph node lymphangiogenesis--impact on cancer metastasis.
[16793912] J Leukoc Biol 80(4): 691-6 (2006)
2006  
37
Effector-phase tolerance: another mechanism of how cancer escapes antitumor immune response.
[16415165] J Leukoc Biol 79(4): 652-62 (2006)
2004  
38
Regulation of interleukin-12 gene expression and its anti-tumor activities by prostaglandin E2 derived from mammary carcinomas.
[15123779] J Leukoc Biol 76(2): 322-32 (2004)
2004  
39
CD1d-restricted "NKT" cells and myeloid IL-12 production: an immunological crossroads leading to promotion or suppression of effective anti-tumor immune responses?
[15123775] J Leukoc Biol 76(2): 307-13 (2004)
2002  
40
Immune escape of tumors: apoptosis resistance and tumor counterattack.
[12050175] J Leukoc Biol 71(6): 907-20 (2002)
2001  
41
Leukocyte recruitment at sites of tumor: dissonant orchestration.
[11493608] J Leukoc Biol 70(2): 171-84 (2001)
1999  
42
Inhibitory and activating receptors involved in immune surveillance by human NK and myeloid cells.
[10577499] J Leukoc Biol 66(5): 718-22 (1999)
1998  
43
Tumor-induced immune dysfunction: the macrophage connection.
[9738653] J Leukoc Biol 64(3): 275-90 (1998)
1996  
44
Human tumor antigens recognized by T lymphocytes: implications for cancer therapy.
[8830785] J Leukoc Biol 60(3): 296-309 (1996)
1994  
45
Cytokine networks in solid human tumors: regulation of angiogenesis.
[7523556] J Leukoc Biol 56(4): 423-35 (1994)
1993  
46
Involvement of inflammatory mediators in macrophage antitumor activity.
[8245715] J Leukoc Biol 54(6): 613-26 (1993)
2009  
47
Mast cells as regulators of adaptive immunity to tumours.
[19077084] Clin Exp Immunol 155(2): 140-6 (2009)
1992  
48
Why are transformed cells immortal? Is the process reversible?
[1590259] Am J Clin Nutr 55(6 Suppl): 1215S-1221S (1992)
1981  
49
Cancer and subversion of host defences.
[6457595] Aust J Exp Biol Med Sci 59(Pt 3): 229-62 (1981)
2005  
50
TGF beta signalling and its role in tumour pathogenesis.
[15990918] Acta Biochim Pol 52(2): 329-37 (2005)
2009  
51
Molecular pathways in tumor progression: from discovery to functional understanding.
[19668850] Mol Biosyst 5(9): 902-8 (2009)
2002  
52
The role of nitric oxide in cancer.
[12528889] Cell Res 12(5-6): 311-20 (2002)
2001  
53
2008  
54
VEGF165 expression in the tumor microenvironment influences the differentiation of bone marrow-derived pericytes that contribute to the Ewing's sarcoma vasculature.
[18344025] Angiogenesis 11(3): 257-67 (2008)
1999  
55
Angiogenic switch and vascular stability in human Leydig cell tumours.
[14517422] Angiogenesis 3(3): 231-40 (1999)
1998  
56
Tumorigenicity depends on angiogenic potential of tumor cells: dominant role of vascular endothelial growth factor and/or fibroblast growth factors produced by tumor cells.
[14517376] Angiogenesis 2(1): 57-66 (1998)
1998  
57
The implications of angiogenesis on tumor invasiveness.
[14517371] Angiogenesis 2(1): 21-3 (1998)
2008  
58
Endocytosis and cancer: an 'insider' network with dangerous liaisons.
[18785924] Traffic 9(12): 2011-21 (2008)
2008  
59
Cancer metastasis as disrupted developmental phenotype.
[19424481] Curr Genomics 9(1): 25-8 (2008)
1992  
60
Functional role of glycosphingolipids in tumor progression.
[1306306] Tohoku J Exp Med 168(2): 211-22 (1992)
2009  
61
Endogenous and induced oxidative stress in multi-cellular tumour spheroids: implications for improving tumour therapy.
[19374249] Indian J Biochem Biophys 46(1): 16-24 (2009)
2006  
62
Tumour angiogenesis: the relevance to surgeons.
[17059709] Ann R Coll Surg Engl 88(6): 525-9 (2006)
1977  
63
2006  
64
Review article: immune suppression and colorectal cancer.
[17014575] Aliment Pharmacol Ther 24(8): 1163-77 (2006)
2002  
65
The angiogenic switch in solid tumors: clinical implications.
[12658894] Suppl Tumori 1(6): S9-11 (2002)
2009  
66
Cell death pathways in response to antitumor therapy.
[19856649] Tumori 95(4): 409-21 (2009)
1991  
67
The exponential-Gompertzian tumor growth model: data from six tumor cell lines in vitro and in vivo. Estimate of the transition point from exponential to Gompertzian growth and potential clinical implications.
[1862544] Tumori 77(3): 189-95 (1991)
1999  
68
The role of the vascular phase in solid tumor growth: a historical review.
[10935483] Neoplasia 1(4): 293-302 (1999)
1999  
69
"...those left behind." Biology and oncology of invasive glioma cells.
[10935475] Neoplasia 1(3): 208-19 (1999)
1999  
70
Causes and effects of heterogeneous perfusion in tumors.
[10935474] Neoplasia 1(3): 197-207 (1999)
2005  
71
The role of serotonin in tumour growth (review).
[16273262] Oncol Rep 14(6): 1593-7 (2005)
2007  
72
Tumor-stroma interactions in pancreatic ductal adenocarcinoma.
[17406031] Mol Cancer Ther 6(4): 1186-97 (2007)
2008  
73
The effects of surgery on tumor growth: a century of investigations.
[18550576] Ann Oncol 19(11): 1821-8 (2008)
2009  
74
Why are tumour blood vessels abnormal and why is it important to know?
[19240721] Br J Cancer 100(6): 865-9 (2009)
2008  
75
Tumour-stroma interactions in colorectal cancer: converging on beta-catenin activation and cancer stemness.
[18506144] Br J Cancer 98(12): 1886-93 (2008)
2005  
76
Tumour-derived exosomes or microvesicles: another mechanism of tumour escape from the host immune system?
[15702078] Br J Cancer 92(2): 209-11 (2005)
1974  
77
Lymphoreticular infiltration in human tumours: prognostic and biological implications: a review.
[4614858] Br J Cancer 30(6): 538-48 (1974)
1966  
78
The growth rate of human tumours.
[5327764] Br J Cancer 20(1): 74-86 (1966)
1988  
79
The immunologic treatment of cancer.
[2450624] CA Cancer J Clin 38(2): 68-94 (1988)
2007  
80
The requirements for CTL-mediated rejection of cancer in humans: NKG2D and its role in the immune responsiveness of melanoma.
[18094399] Clin Cancer Res 13(24): 7228-31 (2007)
2007  
81
Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment.
[17875753] Clin Cancer Res 13(18 Pt 1): 5256-61 (2007)
2007  
82
Reversal of tumor-mediated immunosuppression.
[17255301] Clin Cancer Res 13(2 Pt 2): 727s-732s (2007)
2005  
83
The pathway to biomarker discovery: carbonic anhydrase IX and the prediction of immune responsiveness.
[15897553] Clin Cancer Res 11(10): 3601-3 (2005)
1996  
84
How do lymphocytes kill tumor cells?
[9816231] Clin Cancer Res 2(5): 785-9 (1996)
2007  
85
Drug resistance and the solid tumor microenvironment.
[17895480] J Natl Cancer Inst 99(19): 1441-54 (2007)
2000  
86
Preventing cancer by disrupting progression of precancerous lesions.
[11106670] J Natl Cancer Inst 92(23): 1868-9 (2000)
2008  
87
The use of TLR7 and TLR8 ligands for the enhancement of cancer immunotherapy.
[18701762] Oncologist 13(8): 859-75 (2008)
2008  
88
Impact of the hyaluronan-rich tumor microenvironment on cancer initiation and progression.
[18564137] Cancer Sci 99(9): 1720-5 (2008)
2008  
89
Inflammation and cancer: role of nuclear factor-kappaB activation.
[18294278] Cancer Sci 99(5): 836-42 (2008)
2008  
90
Clinical applications of natural killer T cell-based immunotherapy for cancer.
[18294290] Cancer Sci 99(4): 638-45 (2008)
2008  
91
Roles for deregulated receptor tyrosine kinases and their downstream signaling molecules in hematologic malignancies.
[18177485] Cancer Sci 99(3): 479-85 (2008)
2007  
92
Recklessness as a hallmark of aggressive cancer.
[17725805] Cancer Sci 98(11): 1659-65 (2007)
2007  
93
Therapeutic strategy using phenotypic modulation of cancer cells by differentiation-inducing agents.
[17645578] Cancer Sci 98(11): 1643-51 (2007)
2007  
94
2007  
95
The immortalized cell lines with differentiation potentials: their establishment and possible application.
[17233813] Cancer Sci 98(3): 275-83 (2007)
2006  
96
Genetic instability in cancer cells by impaired cell cycle checkpoints.
[16925578] Cancer Sci 97(10): 984-9 (2006)
2006  
97
Natural killer T cell-mediated antitumor immune responses and their clinical applications.
[16805854] Cancer Sci 97(9): 807-12 (2006)
2003  
98
Tumor hypoxia: a target for selective cancer therapy.
[14662015] Cancer Sci 94(12): 1021-8 (2003)
2003  
99
Cell adhesion system and human cancer morphogenesis.
[12841864] Cancer Sci 94(7): 575-81 (2003)
2008  
100
Targeting the stroma by T cells to limit tumor growth.
[19047130] Cancer Res 68(23): 9570-3 (2008)
2005  
101
Inflammation in the genesis and perpetuation of cancer: summary and recommendations from a national cancer institute-sponsored meeting.
[16204020] Cancer Res 65(19): 8583-6 (2005)
1999  
102
The hypoxic cell: a target for selective cancer therapy--eighteenth Bruce F. Cain Memorial Award lecture.
[10606224] Cancer Res 59(23): 5863-70 (1999)
1998  
103
The unique physiology of solid tumors: opportunities (and problems) for cancer therapy.
[9537241] Cancer Res 58(7): 1408-16 (1998)
1991  
104
The inhibition of tumor growth by tumor mass.
[1988084] Cancer Res 51(1): 2-4 (1991)
1989  
105
Cancer as a disease of DNA organization and dynamic cell structure.
[2653618] Cancer Res 49(10): 2525-32 (1989)
1988  
106
Determinants of tumor blood flow: a review.
[3282647] Cancer Res 48(10): 2641-58 (1988)
1988  
107
Tumors as caricatures of the process of tissue renewal: prospects for therapy by directing differentiation.
[2450643] Cancer Res 48(8): 1996-2004 (1988)
1987  
108
Biological and therapeutic potential of membrane lipid modification in tumors.
[3304617] Cancer Res 47(17): 4529-37 (1987)
1987  
109
Transport of molecules in the tumor interstitium: a review.
[3555767] Cancer Res 47(12): 3039-51 (1987)
1987  
110
The autoimmune nature of cancer.
[3542202] Cancer Res 47(4): 927-32 (1987)
1975  
111
Influence of a new virostatic compound on the induction of enzymes in rat liver.
[24] Arzneimittelforschung 25(9): 1426-9 (1975)
1987  
112
Induction of transformed cells to terminal differentiation and the modulation of gene expression.
[3542191] Cancer Res 47(3): 659-66 (1987)
1984  
113
Perspectives on clonogenic tumor cells, stem cells, and oncogenes.
[6386145] Cancer Res 44(11): 4909-18 (1984)
1984  
114
1976  
115
Cutaneous and muscular rasodilation in the canine hindlimb evoked by central stimulation.
[5204] Circ Res 38(6): 560-6 (1976)
1983  
116
Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture.
[6305486] Cancer Res 43(8): 3466-92 (1983)
1978  
117
Specificity of arrest, survival, and growth of selected metastatic variant cell lines.
[359132] Cancer Res 38(11 Pt 2): 4105-11 (1978)
1978  
118
Chromosomal proteins in transformed and neoplastic cells: a review.
[639052] Cancer Res 38(5): 1181-201 (1978)
1977  
119
A new concept of tissue and tumor cell proliferation.
[332341] Cancer Res 37(11): 3845-62 (1977)
1965  
120
MECHANISM OF LIVER CATALASE DEPRESSION IN TUMOR-BEARING ANIMALS: A REVIEW.
[14254991] Cancer Res 25(-): 34-45 (1965)
1963  
121
SOME BIOCHEMICAL ESSENTIALS OF MALIGNANCY.
[14073548] Cancer Res 23(-): 1474-82 (1963)
1963  
122
SOME PROBLEMS BASIC TO CANCER RESEARCH WITHOUT PARTICULAR REFERENCE TO CHEMOTHERAPY.
[14070374] Cancer Res 23(-): 1186-90 (1963)
1962  
123
The surface properties of cancer cells: a review.
[13858936] Cancer Res 22(-): 525-48 (1962)
1962  
124
The cancer cell in vitro: a review.
[14484477] Cancer Res 22(-): 431-40 (1962)
1960  
125
Nucleic acid synthesis in the neoplastic cell and impact of nuclear changes on the biochemistry of tumor tissue: a review.
[13756437] Cancer Res 20(-): 1121-48 (1960)
1960  
126
Relationships of immunology to cancer: a review.
[13833075] Cancer Res 20(-): 271-91 (1960)
1958  
127
Nuclear proteins of tumors and other tissues: a review.
[13608430] Cancer Res 18(11): 1241-56 (1958)
1958  
128
Immunological enhancement of tumor homografts in mice: a review.
[13596939] Cancer Res 18(9): 992-1003 (1958)
1958  
129
Growth-promoting factors in tissues: a review.
[13596938] Cancer Res 18(9): 981-91 (1958)
1958  
130
Cellular metabolism and cancer: a review.
[13561256] Cancer Res 18(6): 621-56 (1958)
1958  
131
Electron microscopy of tumor cells and tumor viruses; a review.
[13547041] Cancer Res 18(5): 491-509 (1958)
1957  
132
Contributions of tissue culture studies to an understanding of the biology of cancer: a review.
[13489691] Cancer Res 17(10): 929-41 (1957)
1957  
133
Tumors characteristic for certain animal species; a review.
[13472671] Cancer Res 17(9): 823-32 (1957)
1955  
134
Microscopy. III. Cancer cytology and cytochemistry; a review.
[13261075] Cancer Res 15(9): 557-72 (1955)
1954  
135
Growth hormone and adrenocortical hormones in relation to experimental tumors; a review.
[13160947] Cancer Res 14(4): 249-66 (1954)
1953  
136
Conditioned and autonomous neoplasms: a review.
[13067063] Cancer Res 13(7:1): 477-92 (1953)
1952  
137
Some investigations on cell behavior under various conditions; a review.
[13009671] Cancer Res 12(12): 847-60 (1952)
2008  
138
Cadherins and cancer: how does cadherin dysfunction promote tumor progression?
[19029934] Oncogene 27(55): 6920-9 (2008)
2005  
139
2005  
140
The epithelial-mesenchymal transition (EMT) and colorectal cancer progression.
[15846061] Cancer Biol Ther 4(4): 365-70 (2005)
2009  
141
The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment.
[19136477] Carcinogenesis 30(3): 377-86 (2009)
2000  
142
Genome changes and gene expression in human solid tumors.
[10688864] Carcinogenesis 21(3): 443-52 (2000)
2004  
143
2000  
144
Tumor sinuses- vascular channels.
[10936781] Pathol Oncol Res 6(2): 83-6 (2000)
2006  
145
The cancer stem cell: evidence for its origin as an injured autoreactive T cell.
[16478542] Mol Cancer 5(-): 6 (2006)
2003  
146
Molecular responses to hypoxia in tumor cells.
[12740039] Mol Cancer 2(-): 23 (2003)
2006  
147
Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment.
[16513837] Mol Cancer Res 4(2): 61-70 (2006)
2009  
148
Stroma -- regulator of cancer cell progression.
[19783971] Exp Oncol 31(3): 126 (2009)
2009  
149
Tumor hypoxia and malignant progression.
[19550396] Exp Oncol 31(2): 80-6 (2009)
2002  
150
Principles of tumor immunosurveillance and implications for immunotherapy.
[12522443] Cancer Gene Ther 9(12): 1043-55 (2002)
2004  
151
Crosstalk between angiogenesis and lymphangiogenesis in tumor progression.
[15057248] Leukemia 18(6): 1054-8 (2004)
2010  
152
Dual role of complement in tumour growth and metastasis (Review).
[20127033] Int J Mol Med 25(3): 307-13 (2010)
1998  
153
Regulation of cell adhesion, a central mechanism in the anticancer action of essential fatty acids (review).
[9852276] Int J Mol Med 1(3): 621-5 (1998)
2009  
154
Mitochondrial DNA instability and metabolic shift in human cancers.
[19333428] Int J Mol Sci 10(2): 674-701 (2009)
2011  
155
The essential role of evasion from cell death in cancer.
[21704830] Adv Cancer Res 111(-): 39-96 (2011)
2008  
156
The role of NKT cells in tumor immunity.
[19055947] Adv Cancer Res 101(-): 277-348 (2008)
2009  
157
Interaction of indoleamine-2,3-dioxyagnase and CD4+CD25+ regulatory T cells in tumor immune escape.
[19550135] Ai Zheng 28(2): 184-7 (2009)
2002  
158
2010  
159
Transcription factor-mediated epigenetic regulation of cell growth and phenotype for biological control and cancer.
[19896493] Adv Enzyme Regul 50(1): 160-7 (2010)
2011  
160
Understanding tumor-stroma interplays for targeted therapies by armed mesenchymal stromal progenitors: the Mesenkillers.
[22016827] Am J Cancer Res 1(6): 787-805 (2011)
2011  
161
Cancer associated fibroblasts: the dark side of the coin.
[21984967] Am J Cancer Res 1(4): 482-97 (2011)
2010  
162
2002  
163
Tumor microenvironment and the response to anticancer therapy.
[12496469] Cancer Biol Ther 1(5): 453-8 (2002)
2008  
164
Trophinin: what embryo implantation teaches us about human cancer.
[18769125] Cancer Biol Ther 7(8): 1165 (2008)
2003  
165
The complexity of tumor vascularity.
[12878860] Cancer Biol Ther 2(3): 257-8 (2003)
2005  
166
Achieving hypoxia-inducible gene expression in tumors.
[15846086] Cancer Biol Ther 4(4): 359-64 (2005)
2009  
167
Molecular mechanisms of necrosis in glioblastoma: the role of glutamate excitotoxicity.
[19770591] Cancer Biol Ther 8(19): 1791-7 (2009)
2010  
168
Elusive identities and overlapping phenotypes of proangiogenic myeloid cells in tumors.
[20167863] Am J Pathol 176(4): 1564-76 (2010)
2007  
169
Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis.
[16943240] Am J Physiol Cell Physiol 292(3): C987-95 (2007)
2010  
170
The pivotal roles of mitochondria in cancer: Warburg and beyond and encouraging prospects for effective therapies.
[20381449] Biochim Biophys Acta 1797(6-7): 1225-30 (2010)
2010  
171
Tumor heterogeneity: causes and consequences.
[19931353] Biochim Biophys Acta 1805(1): 105-17 (2010)
2010  
172
Pleiotropic roles of matrix metalloproteinases in tumor angiogenesis: contrasting, overlapping and compensatory functions.
[19800930] Biochim Biophys Acta 1803(1): 103-20 (2010)
2010  
173
Metabolic genes in cancer: their roles in tumor progression and clinical implications.
[20122995] Biochim Biophys Acta 1805(2): 141-52 (2010)
2009  
174
Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells.
[19264150] Biochim Biophys Acta 1791(9): 949-55 (2009)
2009  
175
Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation.
[19233249] Biochim Biophys Acta 1796(1): 19-26 (2009)
2009  
176
2008  
177
P53, cyclin-dependent kinase and abnormal amplification of centrosomes.
[18472015] Biochim Biophys Acta 1786(1): 15-23 (2008)
2008  
178
Proteases as modulators of tumor-stromal interaction: primary tumors to bone metastases.
[18082147] Biochim Biophys Acta 1785(2): 85-95 (2008)
2010  
179
The perivascular niche microenvironment in brain tumor progression.
[20714216] Cell Cycle 9(15): 3012-21 (2010)
2006  
180
Negative feedbacks in normal cell growth and their suppression in tumorigenesis.
[16582620] Cell Cycle 5(6): 571-2 (2006)
2006  
181
Stop and go: anti-proliferative and mitogenic functions of the transcription factor C/EBPbeta.
[16687924] Cell Cycle 5(9): 953-7 (2006)
2006  
182
Check, double check: the G2 barrier to cancer.
[16627998] Cell Cycle 5(8): 831-6 (2006)
2006  
183
Brave little world: spheroids as an in vitro model to study tumor-immune-cell interactions.
[16582627] Cell Cycle 5(7): 691-5 (2006)
2011  
184
Could TCTP contribute to Armin Braun's paradigm of tumor reversion in plants?
[21191187] Cell Cycle 10(1): 1 (2011)
2010  
185
The autophagic tumor stroma model of cancer or "battery-operated tumor growth": A simple solution to the autophagy paradox.
[21051947] Cell Cycle 9(21): 4297-306 (2010)
2003  
186
Redirection of oncoproteins to kill cancer cells.
[14504468] Cell Cycle 2(6): 531-3 (2003)
2003  
187
Cell immortality and hallmarks of cancer.
[12851477] Cell Cycle 2(4): 296-9 (2003)
2010  
188
Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes.
[20023378] Cell Cycle 9(2): 260-8 (2010)
2007  
189
What makes tumors multidrug resistant?
[17998803] Cell Cycle 6(22): 2782-7 (2007)
2007  
190
HIF-1-regulated glucose metabolism: a key to apoptosis resistance?
[17404504] Cell Cycle 6(7): 790-2 (2007)
2011  
191
Human umbilical cord blood-derived mesenchymal stem cells and their effect on gliomas.
[21483123] Neurol India 59(2): 226-8 (2011)
2010  
192
Lymphangiogenesis: a new player in cancer progression.
[20731013] World J Gastroenterol 16(32): 4003-12 (2010)
2009  
193
Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.
[19880689] Mayo Clin Proc 84(11): 985-1000 (2009)
2010  
194
Protection from cancer in kidney transplant patients by gammadelta T cells: role of CMV infection?
[20007750] J Am Soc Nephrol 21(1): 11-3 (2010)
2011  
195
Natural killer cells in human cancer: from biological functions to clinical applications.
[21541191] J Biomed Biotechnol 2011(-): 676198 (2011)
2010  
196
Tumor microenvironment and immune effects of antineoplastic therapy in lymphoproliferative syndromes.
[20814546] J Biomed Biotechnol 2010(-): - (2010)
2010  
197
Perforin deficiency and susceptibility to cancer.
[20075937] Cell Death Differ 17(4): 607-15 (2010)
2008  
198
Tumor stress, cell death and the ensuing immune response.
[17992190] Cell Death Differ 15(1): 21-8 (2008)
2008  
199
The 'kiss of death' by dendritic cells to cancer cells.
[17948029] Cell Death Differ 15(1): 58-69 (2008)
2008  
200
Interactions of tumor cells with dendritic cells: balancing immunity and tolerance.
[17948027] Cell Death Differ 15(1): 39-50 (2008)
2008  
201
T-cell death and cancer immune tolerance.
[18007660] Cell Death Differ 15(1): 70-9 (2008)
2009  
202
Semaphorin signaling in cancer cells and in cells of the tumor microenvironment--two sides of a coin.
[19461072] J Cell Sci 122(Pt 11): 1723-36 (2009)
2008  
203
2010  
204
Epithelial-to-mesenchymal transition in pancreatic adenocarcinoma.
[20890584] ScientificWorldJournal 10(-): 1947-57 (2010)
2009  
205
The role of the calcium-sensing receptor in the development and progression of cancer.
[19237714] Endocr Rev 30(2): 178-95 (2009)
2009  
206
Regulation of macrophage function in tumors: the multifaceted role of NF-kappaB.
[19171876] Blood 113(14): 3139-46 (2009)
2006  
207
Regulatory T cells in cancer.
[16861339] Blood 108(3): 804-11 (2006)
2011  
208
Pathophysiological response to hypoxia - from the molecular mechanisms of malady to drug discovery: drug discovery for targeting the tumor microenvironment.
[21422725] J Pharmacol Sci 115(4): 446-52 (2011)
2011  
209
Pathophysiological response to hypoxia - from the molecular mechanisms of malady to drug discovery:hypoxia-inducible factor-1 (HIF-1)-active cells as a target for cancer therapy.
[21422727] J Pharmacol Sci 115(4): 440-5 (2011)
2010  
210
Modeling stromal-epithelial interactions in disease progression.
[20587339] Discov Med 9(49): 504-11 (2010)
2011  
211
Cell lineage specification in tumor progression and metastasis.
[22031670] Discov Med 12(65): 329-40 (2011)
2007  
212
Mechanisms to control rereplication and implications for cancer.
[18053699] Curr Opin Cell Biol 19(6): 663-71 (2007)
2008  
213
The anticancer immune response: indispensable for therapeutic success?
[18523649] J Clin Invest 118(6): 1991-2001 (2008)
2010  
214
Cancer genomics identifies determinants of tumor biology.
[20441611] Genome Biol 11(5): 211 (2010)
2007  
215
Intranuclear changes in cancer cells.
[17764589] Genome Biol 8(8): 312 (2007)
2010  
216
Cancer associated fibroblasts in cancer pathogenesis.
[19896548] Semin Cell Dev Biol 21(1): 33-9 (2010)
2010  
217
Involvement of stromal p53 in tumor-stroma interactions.
[19914385] Semin Cell Dev Biol 21(1): 47-54 (2010)
2010  
218
Proteoglycans: master modulators of paracrine fibroblast-carcinoma cell interactions.
[19931629] Semin Cell Dev Biol 21(1): 66-71 (2010)
2010  
219
Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression.
[19857592] Semin Cell Dev Biol 21(1): 19-25 (2010)
2007  
220
Non-classical major histocompatibility complex proteins as determinants of tumour immunosurveillance.
[17972902] EMBO Rep 8(11): 1024-30 (2007)
2009  
221
IKK/NF-kappaB and STAT3 pathways: central signalling hubs in inflammation-mediated tumour promotion and metastasis.
[19893576] EMBO Rep 10(12): 1314-9 (2009)
2007  
222
Cancer stem cell: target for anti-cancer therapy.
[17625071] FASEB J 21(14): 3777-85 (2007)
2006  
223
Autophagy signaling and the cogwheels of cancer.
[16874041] Autophagy 2(2): 67-73 (2006)
2010  
224
Guidance molecules in lung cancer.
[20139699] Cell Adh Migr 4(1): 130-45 (2010)
2010  
225
Integrin signaling and lung cancer.
[20139694] Cell Adh Migr 4(1): 124-9 (2010)
2007  
226
Viewing malignant melanoma cells as macrophage-tumor hybrids.
[19262091] Cell Adh Migr 1(1): 2-6 (2007)
2009  
227
The role of focal adhesion kinase in tumor initiation and progression.
[19690467] Cell Adh Migr 3(4): 347-50 (2009)
2010  
228
Polarity protein alterations in carcinoma: a focus on emerging roles for polarity regulators.
[20093003] Curr Opin Genet Dev 20(1): 41-50 (2010)
2008  
229
Application of activity-based probes to the study of enzymes involved in cancer progression.
[18294838] Curr Opin Genet Dev 18(1): 97-106 (2008)
2008  
230
Microenvironmental regulation of cancer development.
[18282701] Curr Opin Genet Dev 18(1): 27-34 (2008)
2003  
231
Natural T cell immunity against cancer.
[14555498] Clin Cancer Res 9(12): 4296-303 (2003)
2010  
232
Nuclear factor-kappaB and tumor-associated macrophages.
[20103670] Clin Cancer Res 16(3): 784-9 (2010)
2007  
233
PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma.
[17363529] Clin Cancer Res 13(6): 1757-61 (2007)
2008  
234
Capitalizing on the immunogenicity of dying tumor cells.
[18347160] Clin Cancer Res 14(6): 1603-8 (2008)
2008  
235
The immunogenicity of the hTERT540-548 peptide in cancer.
[18172245] Clin Cancer Res 14(1): 4-7 (2008)
2004  
236
The role of hypoxia-induced factors in tumor progression.
[15591418] Oncologist 9 Suppl 5(-): 10-7 (2004)
2008  
237
Hypoxia and aggressive tumor phenotype: implications for therapy and prognosis.
[18458121] Oncologist 13 Suppl 3(-): 21-6 (2008)
2010  
238
Tumor progression by immune evasion in melanoma: role of the programmed cell death-1/programmed cell death-1 ligand 1 interaction.
[20143442] Cancer 116(7): 1623-5 (2010)
2010  
239
CD73: a novel target for cancer immunotherapy.
[20682793] Cancer Res 70(16): 6407-11 (2010)
2006  
240
Distinct role of macrophages in different tumor microenvironments.
[16423985] Cancer Res 66(2): 605-12 (2006)
2006  
241
Eighteenth annual pezcoller symposium: tumor microenvironment and heterotypic interactions.
[17158190] Cancer Res 66(24): 11550-3 (2006)
2002  
242
What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors?
[11929804] Cancer Res 62(7): 1931-4 (2002)
2002  
243
Significance of blood vessel leakiness in cancer.
[12235011] Cancer Res 62(18): 5381-5 (2002)
2010  
244
Turning on a fuel switch of cancer: hnRNP proteins regulate alternative splicing of pyruvate kinase mRNA.
[20978194] Cancer Res 70(22): 8977-80 (2010)
2010  
245
Modulating tumor vasculature through signaling inhibition to improve cytotoxic therapy.
[20179191] Cancer Res 70(6): 2141-5 (2010)
2007  
246
Tumor angiogenesis: cause or consequence of cancer?
[17671171] Cancer Res 67(15): 7059-61 (2007)
2009  
247
Tumor immunology: new perspectives.
[19738064] Cancer Res 69(18): 7157-9 (2009)
2008  
248
Yin-yang activities and vicious cycles in the tumor microenvironment.
[18172289] Cancer Res 68(1): 9-13 (2008)
2002  
249
Intra-tumoural microvessel density in human solid tumours.
[12085206] Br J Cancer 86(10): 1566-77 (2002)
2011  
250
Patterns in the occurrence and development of tumors.
[21542975] Chin Med J (Engl) 124(7): 1097-104 (2011)
2011  
251
Cancer cells can be tricked into self-destructing.
[21417896] Future Oncol 7(3): 323-5 (2011)
2010  
252
Energy restriction as an antitumor target.
[21142654] Future Oncol 6(11): 1675-9 (2010)
2009  
253
The TGF-beta paradox in human cancer: an update.
[19284383] Future Oncol 5(2): 259-71 (2009)
2007  
254
Pancreas cancer and the role of soluble immunoglobulin-like transcript 3 (ILT3).
[17993722] JOP 8(6): 697-703 (2007)
2007  
255
Insights into the cancer stem cell model of glioma tumorigenesis.
[17549283] Ann Acad Med Singapore 36(5): 352-7 (2007)
2010  
256
Targeting inhibitory pathways in cancer immunotherapy.
[20466529] Curr Opin Immunol 22(3): 385-90 (2010)
2010  
257
Immunity to stemness genes in human cancer.
[20144857] Curr Opin Immunol 22(2): 245-50 (2010)
2010  
258
Adoptive T cell therapy of cancer.
[20171074] Curr Opin Immunol 22(2): 251-7 (2010)
2009  
259
Adoptive immunotherapy of cancer using CD4(+) T cells.
[19285848] Curr Opin Immunol 21(2): 200-8 (2009)
2009  
260
Adoptive transfer of virus-specific and tumor-specific T cell immunity.
[19304470] Curr Opin Immunol 21(2): 224-32 (2009)
2009  
261
Adoptive T cell therapy of cancer.
[19328668] Curr Opin Immunol 21(2): 187-9 (2009)
2008  
262
Peptide epitope identification for tumor-reactive CD4 T cells.
[18499419] Curr Opin Immunol 20(2): 221-7 (2008)
2008  
263
Role of Stat3 in suppressing anti-tumor immunity.
[18479894] Curr Opin Immunol 20(2): 228-33 (2008)
2010  
264
Editorial: PGE2-producing MDSC: a role in tumor progression?
[21041513] J Leukoc Biol 88(5): 827-9 (2010)
2010  
265
Genetic redirection of T cells for cancer therapy.
[20179152] J Leukoc Biol 87(5): 791-803 (2010)
2003  
266
Rational approaches to human cancer immunotherapy.
[12525559] J Leukoc Biol 73(1): 3-29 (2003)
2009  
267
Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation.
[19741157] J Leukoc Biol 86(5): 1065-73 (2009)
2009  
268
Functional plasticity of macrophages: in situ reprogramming of tumor-associated macrophages.
[19605698] J Leukoc Biol 86(5): 1105-9 (2009)
2008  
269
Polarized immune responses differentially regulate cancer development.
[18363999] Immunol Rev 222(-): 145-54 (2008)
2008  
270
Antigen-specific immunotherapy of cervical and ovarian cancer.
[18363994] Immunol Rev 222(-): 43-69 (2008)
2006  
271
CD8+ T-cell memory in tumor immunology and immunotherapy.
[16824130] Immunol Rev 211(-): 214-24 (2006)
2011  
272
PI3K functions in cancer progression, anticancer immunity and immune evasion by tumors.
[22046194] Clin Dev Immunol 2011(-): 947858 (2011)
2011  
273
The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance.
[22110524] Clin Dev Immunol 2011(-): 430394 (2011)
2010  
274
Dendritic cell-based immunotherapy for prostate cancer.
[21076523] Clin Dev Immunol 2010(-): 517493 (2010)
2010  
275
B7-h3 and its role in antitumor immunity.
[21127709] Clin Dev Immunol 2010(-): 683875 (2010)
2010  
276
DNA vaccination: using the patient's immune system to overcome cancer.
[21197271] Clin Dev Immunol 2010(-): 169484 (2010)
2010  
277
T cell-tumor interaction directs the development of immunotherapies in head and neck cancer.
[21234340] Clin Dev Immunol 2010(-): 236378 (2010)
2010  
278
Prognostic and diagnostic value of spontaneous tumor-related antibodies.
[21234352] Clin Dev Immunol 2010(-): 721531 (2010)
2010  
279
Focus on adoptive T cell transfer trials in melanoma.
[21234353] Clin Dev Immunol 2010(-): 260267 (2010)
2010  
280
Theoretical modeling techniques and their impact on tumor immunology.
[21234354] Clin Dev Immunol 2010(-): 271794 (2010)
2010  
281
The initial immune reaction to a new tumor antigen is always stimulatory and probably necessary for the tumor's growth.
[20811480] Clin Dev Immunol 2010(-): - (2010)
2010  
282
Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27.
[20885915] Clin Dev Immunol 2010(-): - (2010)
2010  
283
Vaccines and immunotherapeutics for the treatment of malignant disease.
[20936120] Clin Dev Immunol 2010(-): 697158 (2010)
2010  
284
Glucocorticoid-induced TNFR-related (GITR) protein and its ligand in antitumor immunity: functional role and therapeutic modulation.
[20936139] Clin Dev Immunol 2010(-): 239083 (2010)
2010  
285
Overview of cellular immunotherapy for patients with glioblastoma.
[20953324] Clin Dev Immunol 2010(-): - (2010)
2010  
286
NGcGM3 ganglioside: a privileged target for cancer vaccines.
[21048926] Clin Dev Immunol 2010(-): 814397 (2010)
2010  
287
Regulation of tumor immunity by tumor/dendritic cell fusions.
[21048993] Clin Dev Immunol 2010(-): 516768 (2010)
2010  
288
Harnessing the effect of adoptively transferred tumor-reactive T cells on endogenous (host-derived) antitumor immunity.
[21076522] Clin Dev Immunol 2010(-): 139304 (2010)
2009  
289
Cancer vaccine by fusions of dendritic and cancer cells.
[20182533] Clin Dev Immunol 2009(-): 657369 (2009)
2010  
290
Tumor antigen-dependent and tumor antigen-independent activation of antitumor activity in T cells by a bispecific antibody-modified tumor vaccine.
[21403859] Clin Dev Immunol 2010(-): 423781 (2010)
2010  
291
Immunotherapy of brain cancers: the past, the present, and future directions.
[21437175] Clin Dev Immunol 2010(-): 296453 (2010)
2010  
292
Immune suppression in head and neck cancers: a review.
[21437225] Clin Dev Immunol 2010(-): 701657 (2010)
2010  
293
Tumor immunogenicity and responsiveness to cancer vaccine therapy: the state of the art.
[20226686] Semin Immunol 22(3): 105-12 (2010)
2010  
294
2010  
295
Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.
[20409732] Semin Immunol 22(3): 173-82 (2010)
2011  
296
Epigenetic regulation of cancer-associated genes in ovarian cancer.
[21541038] Int J Mol Sci 12(2): 983-1008 (2011)
2011  
297
New Aspects of Mitochondrial Uncoupling Proteins (UCPs) and Their Roles in Tumorigenesis.
[21954358] Int J Mol Sci 12(8): 5285-93 (2011)
2010  
298
Large non-coding RNAs: missing links in cancer?
[20729297] Hum Mol Genet 19(R2): R152-61 (2010)
2010  
299
Analysis of next-generation genomic data in cancer: accomplishments and challenges.
[20843826] Hum Mol Genet 19(R2): R188-96 (2010)
2007  
300
Epigenetic gene silencing in cancer: the DNA hypermethylome.
[17613547] Hum Mol Genet 16 Spec No 1(-): R50-9 (2007)
2009  
301
Cancer genome sequencing: a review.
[19808792] Hum Mol Genet 18(R2): R163-8 (2009)
2011  
302
Making sense of cancer genomic data.
[21406553] Genes Dev 25(6): 534-55 (2011)
2011  
303
The dynamic nature of autophagy in cancer.
[21979913] Genes Dev 25(19): 1999-2010 (2011)
2007  
304
The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer.
[17875663] Genes Dev 21(18): 2258-70 (2007)
2009  
305
Tumor suppressors and cell metabolism: a recipe for cancer growth.
[19270154] Genes Dev 23(5): 537-48 (2009)
2008  
306
Migratory neighbors and distant invaders: tumor-associated niche cells.
[18316475] Genes Dev 22(5): 559-74 (2008)
2010  
307
Cancer associated fibroblasts (CAFs) in tumor microenvironment.
[20036813] Front Biosci 15(-): 166-79 (2010)
2007  
308
Targeting the tumor microenvironment.
[17485314] Front Biosci 12(-): 3468-74 (2007)
2009  
309
The inflammatory network: bridging senescent stroma and epithelial tumorigenesis.
[19273333] Front Biosci 14(-): 4044-57 (2009)
2009  
310
Harnessing human CD1d restricted T cells for tumor immunity: progress and challenges.
[19273100] Front Biosci 14(-): 796-807 (2009)
2011  
311
The beating heart of melanomas: a minor subset of cancer cells sustains tumor growth.
[21487158] Oncotarget 2(4): 313-20 (2011)
2010  
312
Targeting metabolic remodeling in glioblastoma multiforme.
[21317451] Oncotarget 1(7): 552-62 (2010)
2010  
313
Glutamine addiction: a new therapeutic target in cancer.
[20570523] Trends Biochem Sci 35(8): 427-33 (2010)
2010  
314
The regulation of energy metabolism and the IGF-1/mTOR pathways by the p53 protein.
[20399660] Trends Cell Biol 20(7): 427-34 (2010)
2010  
315
Cross-talk between miRNA and Notch signaling pathways in tumor development and progression.
[20022691] Cancer Lett 292(2): 141-8 (2010)
2010  
316
Purinergic mechanisms in breast cancer support intravasation, extravasation and angiogenesis.
[19926395] Cancer Lett 291(2): 131-41 (2010)
2007  
317
Role of chemokines in tumor growth.
[17629396] Cancer Lett 256(2): 137-65 (2007)
2009  
318
Emerging role of Notch in stem cells and cancer.
[19022563] Cancer Lett 279(1): 8-12 (2009)
2009  
319
Cancer driver mutations in protein kinase genes.
[19081671] Cancer Lett 281(2): 117-27 (2009)
2008  
320
Hypoxia in microscopic tumors.
[18384940] Cancer Lett 264(2): 172-80 (2008)
2008  
321
DNA repair of oxidative DNA damage in human carcinogenesis: potential application for cancer risk assessment and prevention.
[18374480] Cancer Lett 266(1): 60-72 (2008)
2010  
322
Lymphocytes in cancer development: polarization towards pro-tumor immunity.
[20005150] Cytokine Growth Factor Rev 21(1): 3-10 (2010)
2010  
323
Transforming growth factor beta (TGF-beta) and inflammation in cancer.
[20018551] Cytokine Growth Factor Rev 21(1): 49-59 (2010)
2010  
324
Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer.
[20018552] Cytokine Growth Factor Rev 21(1): 11-9 (2010)
2009  
325
Oncogenic stress sensed by the immune system: role of natural killer cell receptors.
[19629084] Nat Rev Immunol 9(8): 568-80 (2009)
2002  
326
Assumptions of the tumor 'escape' hypothesis.
[11926416] Semin Cancer Biol 12(1): 81-6 (2002)
2010  
327
Passenger mutations as a marker of clonal cell lineages in emerging neoplasia.
[20951806] Semin Cancer Biol 20(5): 294-303 (2010)
2010  
328
Physico-mechanical aspects of extracellular matrix influences on tumorigenic behaviors.
[20452434] Semin Cancer Biol 20(3): 139-45 (2010)
2010  
329
Cancer as a reprogramming-like disease: implications in tumor development and treatment.
[20188174] Semin Cancer Biol 20(2): 93-7 (2010)
2007  
330
Tumor immunoediting and immunosculpting pathways to cancer progression.
[17662614] Semin Cancer Biol 17(4): 275-87 (2007)
2007  
331
Inhibitory costimulation and anti-tumor immunity.
[17683946] Semin Cancer Biol 17(4): 288-98 (2007)
2009  
332
Chemokines and the microenvironment in neuroectodermal tumor-host interaction.
[19049876] Semin Cancer Biol 19(2): 92-6 (2009)
2009  
333
Chemokine signaling in cancer: one hump or two?
[18992347] Semin Cancer Biol 19(2): 116-22 (2009)
2008  
334
Can cancer be reversed by engineering the tumor microenvironment?
[18472275] Semin Cancer Biol 18(5): 356-64 (2008)
2008  
335
Adaptation to hypoxia and acidosis in carcinogenesis and tumor progression.
[18455429] Semin Cancer Biol 18(5): 330-7 (2008)
2008  
336
Unraveling the microenvironmental influences on the normal mammary gland and breast cancer.
[18455428] Semin Cancer Biol 18(5): 311-21 (2008)
2008  
337
Using microarrays to study the microenvironment in tumor biology: the crucial role of statistics.
[18455427] Semin Cancer Biol 18(5): 305-10 (2008)
2008  
338
Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells.
[18534864] Semin Cancer Biol 18(4): 244-50 (2008)
2008  
339
Immune escape by Epstein-Barr virus associated malignancies.
[18996483] Semin Cancer Biol 18(6): 381-7 (2008)
2010  
340
Role of senescence and mitotic catastrophe in cancer therapy.
[20205872] Cell Div 5(-): 4 (2010)
2010  
341
Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer.
[20595235] Carcinogenesis 31(9): 1509-15 (2010)
2011  
342
Centromere fission, not telomere erosion, triggers chromosomal instability in human carcinomas.
[21478459] Carcinogenesis 32(6): 796-803 (2011)
2004  
343
Destructive cycles: the role of genomic instability and adaptation in carcinogenesis.
[15180945] Carcinogenesis 25(11): 2033-44 (2004)
2010  
344
Fueling inflammation at tumor microenvironment: the role of multiligand/RAGE axis.
[20028726] Carcinogenesis 31(3): 334-41 (2010)
2010  
345
2009  
346
Metabolic transformation in cancer.
[19321800] Carcinogenesis 30(8): 1269-80 (2009)
2009  
347
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability.
[19468060] Carcinogenesis 30(7): 1073-81 (2009)
2009  
348
Current and potential inflammation targeted therapies in head and neck cancer.
[19570715] Curr Opin Pharmacol 9(4): 389-95 (2009)
2009  
349
Epigenetic alterations in human prostate cancers.
[19520778] Endocrinology 150(9): 3991-4002 (2009)
2002  
350
Regulation of tumour immunity by CD25+ T cells.
[12225357] Immunology 107(1): 5-9 (2002)
2011  
351
2011  
352
2011  
353
The RNA-binding protein Sam68 is a multifunctional player in human cancer.
[21565971] Endocr Relat Cancer 18(4): R91-R102 (2011)
2010  
354
The role of let-7 in cell differentiation and cancer.
[19779035] Endocr Relat Cancer 17(1): F19-36 (2010)
2010  
355
Apoptomirs: small molecules have gained the license to kill.
[19815577] Endocr Relat Cancer 17(1): F37-50 (2010)
2007  
356
Endothelins and hypoxia-inducible factor in cancer.
[17639040] Endocr Relat Cancer 14(2): 233-44 (2007)
2008  
357
Pituitary tumor-transforming gene in endocrine and other neoplasms: a review and update.
[18753362] Endocr Relat Cancer 15(3): 721-43 (2008)
2007  
358
A crucial role of plasma membrane-associated sialidase in the survival of human cancer cells.
[17334392] Oncogene 26(17): 2483-90 (2007)
2011  
359
Beyond reduction of atherosclerosis: PON2 provides apoptosis resistance and stabilizes tumor cells.
[21368884] Cell Death Dis 2(): e112 (2011)
2006  
360
Tumor macrophage redox and effector mechanisms associated with hypoxia.
[17145549] Free Radic Biol Med 41(11): 1621-8 (2006)
2010  
361
Basic and clinical significance of IGF-I-induced signatures in cancer.
[20051101] BMC Med 8(-): 2 (2010)
2010  
362
The proliferating role of insulin and insulin-like growth factors in cancer.
[20663687] Trends Endocrinol Metab 21(10): 610-8 (2010)
2010  
363
Roles for inflammation and regulatory T cells in colon cancer.
[20019355] Toxicol Pathol 38(1): 76-87 (2010)
2009  
364
Visualizing anti-tumor immune responses in vivo.
[19259379] Dis Model Mech 2(3-4): 107-10 (2009)
2010  
365
The yin and yang of vitamin D receptor (VDR) signaling in neoplastic progression: operational networks and tissue-specific growth control.
[19737544] Biochem Pharmacol 79(1): 1-9 (2010)
2010  
366
Defining the pathway to insulin-like growth factor system targeting in cancer.
[20599789] Biochem Pharmacol 80(8): 1115-24 (2010)
2010  
367
Key signalling nodes in mammary gland development and cancer. The Snail1-Twist1 conspiracy in malignant breast cancer progression.
[20594364] Breast Cancer Res 12(3): 206 (2010)
2005  
368
Keystone symposium: the role of microenvironment in tumor induction and progression, Banff, Canada, 5-10 February 2005.
[15987441] Breast Cancer Res 7(3): 113-8 (2005)
2010  
369
Roles for the type III TGF-beta receptor in human cancer.
[20153821] Cell Signal 22(8): 1163-74 (2010)
2009  
370
Inflammatory signaling and cellular senescence.
[18992324] Cell Signal 21(3): 378-83 (2009)
2009  
371
Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies.
[19491931] Eur J Hum Genet 17(12): 1668-75 (2009)
2007  
372
2007  
373
2012  
374
The role of the TRPV6 channel in cancer.
[22331416] J Physiol 590(Pt 6): 1369-76 (2012)
2002  
375
Calcium-selective ion channel, CaT1, is apically localized in gastrointestinal tract epithelia and is aberrantly expressed in human malignancies.
[12480925] Lab Invest 82(12): 1755-64 (2002)
2010  
376
From tumor immunology to cancer immunotherapy: miles to go.
[21358075] J Cancer Res Ther 6(4): 427-31 (2010)
2009  
377
Glucose deprivation-induced metabolic oxidative stress and cancer therapy.
[20009288] J Cancer Res Ther 5 Suppl 1(-): S2-6 (2009)
2009  
378
Tumors show enhanced dependency on glucose and glycolytic pathway.
[20009286] J Cancer Res Ther 5 Suppl 1(-): S1 (2009)
2009  
379
Dysregulation of the mTOR pathway secondary to mutations or a hostile microenvironment contributes to cancer and poor wound healing.
[19209152] J Invest Dermatol 129(3): 529-31 (2009)
2011  
380
Impact of tumour volume on the potential efficacy of therapeutic vaccines.
[21655153] Curr Oncol 18(3): e150-7 (2011)
2009  
381
Role of tissue factor in cancer.
[19738116] J Clin Oncol 27(29): 4834-8 (2009)
2010  
382
The shunt problem: control of functional shunting in normal and tumour vasculature.
[20631803] Nat Rev Cancer 10(8): 587-93 (2010)
2010  
383
2010  
384
2011  
385
Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic.
[21711234] Curr Pharm Des 17(19): 1970-8 (2011)
2009  
386
MicroRNA involvement in the pathogenesis of neuroblastoma: potential for microRNA mediated therapeutics.
[19199973] Curr Pharm Des 15(4): 456-62 (2009)
2008  
387
2004  
388
2011  
389
Platelet-derived growth factor signaling in human malignancies.
[21880178] Chin J Cancer 30(9): 581-4 (2011)
2011  
390
Mitochondria in cancer: at the crossroads of life and death.
[21801601] Chin J Cancer 30(8): 526-39 (2011)
2010  
391
CXCR7 in tumorigenesis and progression.
[20346226] Chin J Cancer 29(4): 456-9 (2010)
2011  
392
Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets.
[21381902] Expert Rev Med Devices 8(2): 123-6 (2011)
2012  
393
Tumor angiogenesis: pericytes and maturation are not to be ignored.
[22007214] J Oncol 2012(-): 261750 (2012)
2010  
394
Angiogenesis and lymphangiogenesis of gastric cancer.
[20369064] J Oncol 2010(-): 468725 (2010)
2010  
395
Vascular endothelial growth factor-related pathways in hemato-lymphoid malignancies.
[20508816] J Oncol 2010(-): 729725 (2010)
2010  
396
Tumor angiogenesis: insights and innovations.
[20445741] J Oncol 2010(-): 132641 (2010)
2010  
397
Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation.
[20490273] J Oncol 2010(-): 201026 (2010)
2010  
398
The pathology of EMT in mouse mammary tumorigenesis.
[20521088] J Mammary Gland Biol Neoplasia 15(2): 225-33 (2010)
2010  
399
Epithelial-mesenchymal transition in cancer: parallels between normal development and tumor progression.
[20490631] J Mammary Gland Biol Neoplasia 15(2): 117-34 (2010)
2010  
400
Snail family regulation and epithelial mesenchymal transitions in breast cancer progression.
[20455012] J Mammary Gland Biol Neoplasia 15(2): 135-47 (2010)
2010  
401
Matrix metalloproteinase-induced epithelial-mesenchymal transition in breast cancer.
[20440544] J Mammary Gland Biol Neoplasia 15(2): 201-12 (2010)
2010  
402
ErbB/EGF signaling and EMT in mammary development and breast cancer.
[20369376] J Mammary Gland Biol Neoplasia 15(2): 191-9 (2010)
2011  
403
Breast Tumor Angiogenesis and Tumor-Associated Macrophages: Histopathologist's Perspective.
[21747968] Patholog Res Int 2011(-): 572706 (2011)
2011  
404
Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review.
[21904528] Front Pharmacol 2(-): 49 (2011)
2010  
405
New advances on critical implications of tumor- and metastasis-initiating cells in cancer progression, treatment resistance and disease recurrence.
[20552555] Histol Histopathol 25(8): 1057-73 (2010)
2010  
406
Fucosylation and gastrointestinal cancer.
[21160988] World J Hepatol 2(4): 151-61 (2010)
2007  
407
Tumor microvasculature and microenvironment: targets for anti-angiogenesis and normalization.
[17560615] Microvasc Res 74(2-3): 72-84 (2007)
2010  
408
Tumor-initiating and -propagating cells: cells that we would like to identify and control.
[20651980] Neoplasia 12(7): 506-15 (2010)
2006  
409
Circulating endothelial cells, endothelial progenitor cells, and endothelial microparticles in cancer.
[16611400] Neoplasia 8(2): 79-88 (2006)
2011  
410
Cancer-associated fibroblasts and their putative role in potentiating the initiation and development of epithelial ovarian cancer.
[21532880] Neoplasia 13(5): 393-405 (2011)
2009  
411
Stromal cells and integrins: conforming to the needs of the tumor microenvironment.
[20019834] Neoplasia 11(12): 1264-71 (2009)
2010  
412
Myofibroblast stromal presence and distribution in squamous epithelial carcinomas, oral dysplasia and hyperkeratosis.
[20843116] Asian Pac J Cancer Prev 11(2): 359-64 (2010)
2010  
413
Molecular regulation of vasculogenic mimicry in tumors and potential tumor-target therapy.
[21160860] World J Gastrointest Surg 2(4): 117-27 (2010)
2010  
414
Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models.
[20374484] Microcirculation 17(3): 206-25 (2010)
2011  
415
Transgenic and knockout mice models to reveal the functions of tumor suppressor genes.
[21836819] Clin Med Insights Oncol 5(-): 235-57 (2011)
2011  
416
Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System.
[22084619] Clin Med Insights Oncol 5(-): 265-314 (2011)
2009  
417
Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4.
[19513941] Curr Opin Investig Drugs 10(6): 526-35 (2009)
2009  
418
2010  
419
Chemokines: can effector cells be redirected to the site of the tumor?
[20693843] Cancer J 16(4): 325-35 (2010)
2010  
420
Extracellular matrix: a gatekeeper in the transition from dormancy to metastatic growth.
[20304630] Eur J Cancer 46(7): 1181-8 (2010)
2011  
421
Tumor induced inactivation of natural killer cell cytotoxic function; implication in growth, expansion and differentiation of cancer stem cells.
[21850212] J Cancer 2(-): 443-57 (2011)
2010  
422
The extracellular matrix in digestive cancer.
[21209783] Cancer Microenviron 3(1): 177-85 (2010)
2011  
423
Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer.
[21909876] Cancer Microenviron 4(2): 141-54 (2011)
2010  
424
Myeloid cells in cancer progression: unique subtypes and their roles in tumor growth, vascularity, and host immune suppression.
[21505557] Cancer Microenviron 4(1): 1-11 (2010)
2010  
425
T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets.
[21209773] Cancer Microenviron 3(1): 29-47 (2010)
2010  
426
The tumor microenvironment in colorectal carcinogenesis.
[21209781] Cancer Microenviron 3(1): 149-66 (2010)
2010  
427
A digest on the role of the tumor microenvironment in gastrointestinal cancers.
[21209782] Cancer Microenviron 3(1): 167-76 (2010)
2010  
428
The tumor microenvironment in non-small-cell lung cancer.
[20685578] Semin Radiat Oncol 20(3): 156-63 (2010)
2010  
429
The tumor microenvironment and DNA repair.
[20832021] Semin Radiat Oncol 20(4): 282-7 (2010)
2009  
430
Role of the hypoxic tumor microenvironment in the resistance to anti-angiogenic therapies.
[19394890] Drug Resist Updat 12(3): 74-80 (2009)
2009  
431
2009  
432
Impaired DNA damage response--an Achilles' heel sensitizing cancer to chemotherapy and radiotherapy.
[19836377] Eur J Pharmacol 625(1-3): 143-50 (2009)
2011  
433
Two Endogenous Antiangiogenic Inhibitors, Endostatin and Angiostatin, Demonstrate Biphasic Curves in their Antitumor Profiles.
[22013399] Dose Response 9(3): 369-76 (2011)
2009  
434
Targeting the Warburg effect in hematological malignancies: from PET to therapy.
[19587591] Curr Opin Oncol 21(6): 531-6 (2009)
2009  
435
Behavior of immune players in the tumor microenvironment.
[19125019] Curr Opin Oncol 21(1): 53-9 (2009)
2003  
436
Tumor reversion: correction of malignant behavior by microenvironmental cues.
[14566816] Int J Cancer 107(5): 688-95 (2003)
2009  
437
Activated macrophages in the tumour microenvironment-dancing to the tune of TLR and NF-kappaB.
[19662665] J Pathol 219(2): 143-52 (2009)
2007  
438
2002  
439
Order and disorder: the role of extracellular matrix in epithelial cancer.
[11852996] Cancer Invest 20(1): 139-53 (2002)
2005  
440
Nucleolar adaptation in human cancer.
[16305988] Cancer Invest 23(7): 599-608 (2005)
2002  
441
Wnt/beta-catenin/tcf signaling: a critical pathway in gastrointestinal tumorigenesis.
[12481159] Digestion 66(3): 131-44 (2002)
2006  
442
The role of the hypoxia-inducible factor in tumor metabolism growth and invasion.
[16935775] Bull Cancer 93(8): E73-80 (2006)
2009  
443
Cancer and the tumor microenvironment: a review of an essential relationship.
[19083000] Cancer Chemother Pharmacol 63(4): 571-82 (2009)
2010  
444
The role of tregs in glioma-mediated immunosuppression: potential target for intervention.
[19944972] Neurosurg Clin N Am 21(1): 125-37 (2010)
2008  
445
Use of mouse models to study the role of tissue factor in tumor biology.
[18645923] Semin Thromb Hemost 34(2): 182-6 (2008)
2007  
446
Aberrant regulation of messenger RNA 3'-untranslated region in human cancer.
[17429137] Cell Oncol 29(1): 1-17 (2007)
2011  
447
The Cain and Abl of epithelial-mesenchymal transition and transforming growth factor-β in mammary epithelial cells.
[21051857] Cells Tissues Organs 193(1-2): 98-113 (2011)
2007  
448
Role of the metabolic stress responses of apoptosis and autophagy in tumor suppression.
[18811051] Ernst Schering Found Symp Proc -(4): 23-34 (2007)
2010  
449
Adipose tissue-derived progenitor cells and cancer.
[21607127] World J Stem Cells 2(5): 103-13 (2010)
2010  
450
The bad and the good of mesenchymal stem cells in cancer: Boosters of tumor growth and vehicles for targeted delivery of anticancer agents.
[21607110] World J Stem Cells 2(1): 5-12 (2010)
2009  
451
The role of autophagy in tumour development and cancer therapy.
[19951459] Expert Rev Mol Med 11(-): e36 (2009)
2010  
452
Up for Mischief? IL-17/Th17 in the tumour microenvironment.
[20729908] Oncogene 29(42): 5653-62 (2010)
2011  
453
NF-κB addiction and its role in cancer: 'one size does not fit all'.
[21170083] Oncogene 30(14): 1615-30 (2011)
2010  
454
Metabolism and proliferation share common regulatory pathways in cancer cells.
[20514019] Oncogene 29(31): 4369-77 (2010)
2010  
455
Cancer-selective apoptotic effects of extracellular and intracellular Par-4.
[20440265] Oncogene 29(27): 3873-80 (2010)
2008  
456
Par complex in cancer: a regulator of normal cell polarity joins the dark side.
[19029931] Oncogene 27(55): 6878-87 (2008)
2008  
457
Biomechanical regulation of cell orientation and fate.
[19029939] Oncogene 27(55): 6981-93 (2008)
2010  
458
Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics.
[19946328] Oncogene 29(5): 625-34 (2010)
2008  
459
FOXOs, cancer and regulation of apoptosis.
[18391973] Oncogene 27(16): 2312-9 (2008)
2010  
460
CD20+ B cells: the other tumor-infiltrating lymphocytes.
[20962266] J Immunol 185(9): 4977-82 (2010)
2009  
461
Protumor vs antitumor functions of IL-17.
[19767566] J Immunol 183(7): 4169-75 (2009)
2010  
462
Intravital imaging of anti-tumor immune response and the tumor microenvironment.
[20652252] Semin Immunopathol 32(3): 305-17 (2010)
2010  
463
2010  
464
p53 connects tumorigenesis and reprogramming to pluripotency.
[20876313] J Exp Med 207(10): 2045-8 (2010)
2009  
465
A20 takes on tumors: tumor suppression by an ubiquitin-editing enzyme.
[19380636] J Exp Med 206(5): 977-80 (2009)
2010  
466
TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression.
[20538542] Trends Immunol 31(6): 220-7 (2010)
2009  
467
Is complement good or bad for cancer patients? A new perspective on an old dilemma.
[19428302] Trends Immunol 30(6): 286-92 (2009)
2011  
468
The Role of p53 in Metabolic Regulation.
[21779507] Genes Cancer 2(4): 385-91 (2011)
2006  
469
Clinicopathological significance of stromal variables: angiogenesis, lymphangiogenesis, inflammatory infiltration, MMP and PINCH in colorectal carcinomas.
[17026740] Mol Cancer 5(-): 43 (2006)
2006  
470
Epigenetic aberrations and cancer.
[17092350] Mol Cancer 5(-): 60 (2006)
2006  
471
Tumor cell metabolism: the marriage of molecular genetics and proteomics with cellular intermediary metabolism; proceed with caution!
[17090311] Mol Cancer 5(-): 59 (2006)
2011  
472
The metabolic advantage of tumor cells.
[21649891] Mol Cancer 10(-): 70 (2011)
2011  
473
The functional role of long non-coding RNA in human carcinomas.
[21489289] Mol Cancer 10(-): 38 (2011)
2010  
474
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity.
[20405169] Cancer Metastasis Rev 29(2): 309-16 (2010)
2010  
475
Senescent cells as a source of inflammatory factors for tumor progression.
[20390322] Cancer Metastasis Rev 29(2): 273-83 (2010)
2011  
476
Tumor immunosurveillance in human cancers.
[21249426] Cancer Metastasis Rev 30(1): 5-12 (2011)
2011  
477
DNA repair: the culprit for tumor-initiating cell survival?
[21340664] Cancer Metastasis Rev 30(2): 185-97 (2011)
2009  
478
Urothelial carcinoma: stem cells on the edge.
[20012172] Cancer Metastasis Rev 28(3-4): 291-304 (2009)
2007  
479
Tumour vascularization: sprouting angiogenesis and beyond.
[17717633] Cancer Metastasis Rev 26(3-4): 489-502 (2007)
2010  
480
Sterile' inflammation and autophagy in cancer immunotherapy.
[20874641] Immunotherapy 2(5): 599-601 (2010)
2011  
481
Tumor-reactive CD4+ T cells: plasticity beyond helper and regulatory activities.
[21843076] Immunotherapy 3(8): 915-7 (2011)
2004  
482
Stromal fibroblasts in cancer initiation and progression.
[15549095] Nature 432(7015): 332-7 (2004)
2009  
483
2008  
484
Translating insights from the cancer genome into clinical practice.
[18385729] Nature 452(7187): 553-63 (2008)
2011  
485
Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth?
[21280155] Stem Cells 29(1): 11-9 (2011)
2003  
486
Hypoxia-induced angiogenesis during carcinogenesis.
[12542982] J Biochem Mol Biol 36(1): 120-7 (2003)
2003  
487
Roles of matrix metalloproteinases in tumor metastasis and angiogenesis.
[12542983] J Biochem Mol Biol 36(1): 128-37 (2003)
2010  
488
Danger signals in tumor cells: a risk factor for autoimmune disease?
[20370543] Expert Rev Vaccines 9(4): 347-50 (2010)
2011  
489
Epigenetic changes of DNA repair genes in cancer.
[21278452] J Mol Cell Biol 3(1): 51-8 (2011)
2010  
490
Context-dependent regulation of the GLI code in cancer by HEDGEHOG and non-HEDGEHOG signals.
[20083481] J Mol Cell Biol 2(2): 84-95 (2010)
2010  
491
Proton dynamics in cancer.
[20550689] J Transl Med 8(-): 57 (2010)
2011  
492
Understanding tumor heterogeneity as functional compartments--superorganisms revisited.
[21619636] J Transl Med 9(-): 79 (2011)
2011  
493
Tumour macrophages as potential targets of bisphosphonates.
[22005011] J Transl Med 9(-): 177 (2011)
2009  
494
CRP identifies homeostatic immune oscillations in cancer patients: a potential treatment targeting tool?
[19948067] J Transl Med 7(-): 102 (2009)
2010  
495
Small mitochondria-targeting molecules as anti-cancer agents.
[19995573] Mol Aspects Med 31(1): 75-92 (2010)
2009  
496
Emerging roles of microRNAs as molecular switches in the integrated circuit of the cancer cell.
[19561119] RNA 15(8): 1443-61 (2009)
2010  
497
Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression.
[20415597] Expert Opin Biol Ther 10(7): 1019-35 (2010)
2010  
498
Immune-based therapeutics for pediatric cancer.
[19947897] Expert Opin Biol Ther 10(2): 163-78 (2010)
2011  
499
Intratumoral expression of IL-17 and its prognostic role in gastric adenocarcinoma patients.
[21234303] Int J Biol Sci 7(1): 53-60 (2011)
2011  
500
Dual roles of immune cells and their factors in cancer development and progression.
[21647333] Int J Biol Sci 7(5): 651-8 (2011)
2008  
501
Dysregulation of apoptotic signaling in cancer: molecular mechanisms and therapeutic opportunities.
[18459149] J Cell Biochem 104(4): 1124-49 (2008)
2007  
502
Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT?
[17211838] J Cell Biochem 101(4): 830-9 (2007)
2009  
503
2006  
504
Tumor-infiltrating T lymphocytes: friends or foes?
[16446705] Lab Invest 86(3): 231-45 (2006)
2010  
505
Dueling models in head and neck tumor formation.
[21030945] Lab Invest 90(11): 1546-8 (2010)
2010  
506
Roles of small RNAs in tumor formation.
[20493775] Trends Mol Med 16(6): 257-67 (2010)
2010  
507
p53 post-translational modification: deregulated in tumorigenesis.
[20932800] Trends Mol Med 16(11): 528-36 (2010)
2010  
508
Hijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells.
[20022559] Trends Mol Med 16(1): 17-26 (2010)
2010  
509
Chemokines and chemokine receptors: new insights into cancer-related inflammation.
[20163989] Trends Mol Med 16(3): 133-44 (2010)
2009  
510
Brain cancer propagating cells: biology, genetics and targeted therapies.
[19889578] Trends Mol Med 15(11): 519-30 (2009)
2010  
511
Quasispecies theory and the behavior of RNA viruses.
[20661479] PLoS Pathog 6(7): e1001005 (2010)
2011  
512
Inborn and acquired metabolic defects in cancer.
[21301796] J Mol Med (Berl) 89(3): 213-20 (2011)
2009  
513
Epigenetic disruption of the WNT/beta-catenin signaling pathway in human cancers.
[19633433] Epigenetics 4(5): 307-12 (2009)
2010  
514
Pharmaco-epigenomics: discovering therapeutic approaches and biomarkers for cancer therapy.
[20389307] Heredity (Edinb) 105(1): 152-60 (2010)
2010  
515
Matrix metalloproteinases: regulators of the tumor microenvironment.
[20371345] Cell 141(1): 52-67 (2010)
2009  
516
Hypoxic tumor microenvironment and cancer cell differentiation.
[19519400] Curr Mol Med 9(4): 425-34 (2009)
2009  
517
Novel imaging provides new insights into mechanisms of oxygen transport in tumors.
[19519401] Curr Mol Med 9(4): 435-41 (2009)
2009  
518
Hypoxia and radiation therapy: past history, ongoing research, and future promise.
[19519402] Curr Mol Med 9(4): 442-58 (2009)
2009  
519
The contrasting roles of NKT cells in tumor immunity.
[19689293] Curr Mol Med 9(6): 667-72 (2009)
2010  
520
Extracellular matrix genes as hypoxia-inducible targets.
[19662436] Cell Tissue Res 339(1): 19-29 (2010)
2009  
521
Imaging and quantifying the dynamics of tumor-associated proteolysis.
[19082919] Clin Exp Metastasis 26(4): 299-309 (2009)
2005  
522
The fibroblastic coconspirator in cancer progression.
[16869775] Cold Spring Harb Symp Quant Biol 70(-): 383-8 (2005)
2011  
523
Hypoxic regulation of glycosylation via the N-acetylglucosamine cycle.
[21297907] J Clin Biochem Nutr 48(1): 20-5 (2011)
2011  
524
The immunoregulatory mechanisms of carcinoma for its survival and development.
[21255410] J Exp Clin Cancer Res 30(-): 12 (2011)
2010  
525
Proton pump inhibitors as anti vacuolar-ATPases drugs: a novel anticancer strategy.
[20459683] J Exp Clin Cancer Res 29(-): 44 (2010)
2010  
526
Oncoprotein metastasis and its suppression revisited.
[20380702] J Exp Clin Cancer Res 29(-): 30 (2010)
2008  
527
Role of Smac/DIABLO in cancer progression.
[18822137] J Exp Clin Cancer Res 27(-): 48 (2008)
2010  
528
Cancer and inflammation: promise for biologic therapy.
[20386472] J Immunother 33(4): 335-51 (2010)
2008  
529
Roles of bioactive sphingolipids in cancer biology and therapeutics.
[18751921] Subcell Biochem 49(-): 413-40 (2008)
2011  
530
3D tumour models: novel in vitro approaches to cancer studies.
[21499821] J Cell Commun Signal 5(3): 239-48 (2011)
2009  
531
Mutational spectra of human cancer.
[19308457] Hum Genet 125(5-6): 493-506 (2009)
2011  
532
Appetite for destruction: the inhibition of glycolysis as a therapy for tuberous sclerosis complex-related tumors.
[22018140] BMC Biol 9(-): 69 (2011)
2009  
533
PrognoScan: a new database for meta-analysis of the prognostic value of genes.
[19393097] BMC Med Genomics 2(-): 18 (2009)
2009  
534
Paradoxical roles of IL-4 in tumor immunity.
[20003817] Cell Mol Immunol 6(6): 415-22 (2009)
2009  
535
Dynamic behavior and function of Foxp3+ regulatory T cells in tumor bearing host.
[19254475] Cell Mol Immunol 6(1): 3-13 (2009)
2011  
536
The role of morphine in regulation of cancer cell growth.
[21800094] Naunyn Schmiedebergs Arch Pharmacol 384(3): 221-30 (2011)
2011  
537
IFN-γ, IL-17 and TGF-β involvement in shaping the tumor microenvironment: The significance of modulating such cytokines in treating malignant solid tumors.
[21943203] Cancer Cell Int 11(-): 33 (2011)
2010  
538
Testing the theory of immune selection in cancers that break the rules of transplantation.
[20033157] Cancer Immunol Immunother 59(5): 643-51 (2010)
2009  
539
Mechanisms of murine dendritic cell antitumor dysfunction in aging.
[19082999] Cancer Immunol Immunother 58(12): 1935-9 (2009)
2009  
540
A systematic review of humoral immune responses against tumor antigens.
[19562338] Cancer Immunol Immunother 58(10): 1535-44 (2009)
2011  
541
Epithelial-Mesenchymal Transition in tumor microenvironment.
[21880137] Cell Biosci 1(-): 29 (2011)
2010  
542
Preferential killing of cancer cells with mitochondrial dysfunction by natural compounds.
[20713185] Mitochondrion 10(6): 614-25 (2010)
2007  
543
15-hydroxyprostaglandin dehydrogenase (15-PGDH) and lung cancer.
[17481556] Prostaglandins Other Lipid Mediat 83(3): 203-8 (2007)
2010  
544
Tumors as organs: complex tissues that interface with the entire organism.
[20627072] Dev Cell 18(6): 884-901 (2010)
2010  
545
Comparative study of tumorigenesis and tumor immunity in invertebrates and nonmammalian vertebrates.
[20553753] Dev Comp Immunol 34(9): 915-25 (2010)
2010  
546
Tolerogenic dendritic cells and myeloid-derived suppressor cells: potential for regulation and therapy of liver auto- and alloimmunity.
[20605054] Immunobiology 215(9-10): 698-703 (2010)
2004  
547
Role of stromal-epithelial interactions in hormonal responses.
[15781983] Arch Histol Cytol 67(5): 417-34 (2004)
2007  
548
Polymers to direct cell fate by controlling the microenvironment.
[18024105] Curr Opin Biotechnol 18(5): 448-53 (2007)
2009  
549
Wnt/Planar cell polarity signaling: a new paradigm for cancer therapy.
[19671746] Mol Cancer Ther 8(8): 2103-9 (2009)
2010  
550
MicroRNA-21: a novel therapeutic target in human cancer.
[21139417] Cancer Biol Ther 10(12): 1224-32 (2010)
2010  
551
Cytochrome P450-derived eicosanoids: the neglected pathway in cancer.
[20941528] Cancer Metastasis Rev 29(4): 723-35 (2010)
2010  
552
Perspectives on the mesenchymal origin of metastatic cancer.
[20839033] Cancer Metastasis Rev 29(4): 695-707 (2010)
2010  
553
Imaging cycling tumor hypoxia.
[21159626] Cancer Res 70(24): 10019-23 (2010)
2010  
554
Targeting hypoxic cells through the DNA damage response.
[20876254] Clin Cancer Res 16(23): 5624-9 (2010)
2010  
555
Cancer: evolutionary, genetic and epigenetic aspects.
[22704202] Clin Epigenetics 1(3-4): 85-100 (2010)
2010  
556
The sirtuins in the pathogenesis of cancer.
[22704201] Clin Epigenetics 1(3-4): 71-83 (2010)
2010  
557
The crosstalk of RAS with the TGF-beta family during carcinoma progression and its implications for targeted cancer therapy.
[20718708] Curr Cancer Drug Targets 10(8): 849-57 (2010)
2011  
558
Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment.
[21185705] Curr Opin Immunol 23(2): 286-92 (2011)
2011  
559
Dissecting DNA hypermethylation in cancer.
[21146531] FEBS Lett 585(13): 2078-86 (2011)
2010  
560
Microenvironment and pathogenesis of epithelial ovarian cancer.
[21761359] Horm Cancer 1(6): 277-90 (2010)
2010  
561
Colorectal cancer cells - Proliferation, survival and invasion by lysophosphatidic acid.
[20932934] Int J Biochem Cell Biol 42(12): 1907-10 (2010)
2011  
562
The sensors and regulators of cell-matrix surveillance in anoikis resistance of tumors.
[20949625] Int J Cancer 128(4): 743-52 (2011)
2010  
563
Aging-related alterations in the extracellular matrix modulate the microenvironment and influence tumor progression.
[21351253] Int J Cancer 127(12): 2739-48 (2010)
2010  
564
Clinical implications of the cancer genome.
[20975063] J Clin Oncol 28(35): 5219-28 (2010)
2010  
565
The tumor-immune microenvironment and response to radiation therapy.
[21161342] J Mammary Gland Biol Neoplasia 15(4): 411-21 (2010)
2010  
566
Microenvironmental influences that drive progression from benign breast disease to invasive breast cancer.
[21161341] J Mammary Gland Biol Neoplasia 15(4): 389-97 (2010)
2010  
567
Glutaminase: a hot spot for regulation of cancer cell metabolism?
[21234284] Oncotarget 1(8): 734-40 (2010)
2010  
568
The role of the TGF-beta coreceptor endoglin in cancer.
[21170488] ScientificWorldJournal 10(): 2367-84 (2010)
2011  
569
Metastasis suppressors and the tumor microenvironment.
[21168504] Semin Cancer Biol 21(2): 113-22 (2011)
2010  
570
Cancer immunotherapy by immunosuppression.
[21159199] Theor Biol Med Model 7(): 45 (2010)
2010  
571
Cell cyclins: triggering elements of cancer or not?
[21176227] World J Surg Oncol 8(): 111 (2010)
2010  
572
Addressing tumour tolerance to improve cancer immunotherapy.
[21110313] Eur J Immunol 40(12): 3302-5 (2010)
PMC   
573
Field cancerization in the colon: a role for aberrant DNA methylation?
[24760232] Gastroenterol Rep (Oxf) 2(1):16-20 (2014)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.



  • Neubildung (Tumorbiologie und Immunologie)

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia